Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-01-29 18:55:12
Reporting Period:
Accepted Time:
2019-01-29 18:55:12
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1435744 Thomas Desrosier C/o Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
Chief Legal Officer And Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-01-26 15,000 $0.00 21,525 No 4 M Direct
Common Stock Disposition 2019-01-28 5,471 $5.75 16,054 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock STOCK OPTION (RIGHT TO BUY) Acquisiton 2019-01-25 84,800 $0.00 84,800 $6.01
Common Stock RESTRICTED STOCK UNITS Disposition 2019-01-26 15,000 $0.00 15,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
84,800 2029-01-24 No 4 A Direct
25,000 No 4 M Direct
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.75 to $5.8435. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
  4. These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.